Skip to content

Effect of Vitamin A in the Treatment of Neonatal Sepsis and Necrotizing Enterocolitis

Effect of Vitamin A in the Treatment of Sepsis and Necrotizing Enterocolitis in Hospitalized Neonates

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00707785
Enrollment
424
Registered
2008-07-01
Start date
2006-12-31
Completion date
2012-06-30
Last updated
2013-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Meningitis, Necrotizing Enterocolitis, Pneumonia, Sepsis

Keywords

vitamin A, Treatment, neonates, newborn, sepsis, necrotizing enterocolitis, meningitis, pneumonia

Brief summary

The purpose of the study is to determine whether vitamin A can improve survival and facilitate recovery from sepsis and necrotizing enterocolitis in hospitalized neonates.

Detailed description

Sepsis and necrotizing enterocolitis (NEC) are leading causes of morbidity and mortality in neonates. Studies have shown that early reversal of the signs associated with severe disease is an important prognostic factor during acute illness. Vitamin A deficiency is widespread among children, including neonates, in developing countries. Vitamin A plays an important role in mediating immune responses and in maintaining epithelial integrity. For this reason vitamin A supplementation during the acute phase of neonatal infection could work synergistically with present antibiotic regimens in promoting early reversal of signs associated with adverse outcome and shorten the total duration of clinical illness. The purpose of the proposed hospital-based clinical trial is to evaluate the efficacy of vitamin A supplementation on reducing the morbidity and mortality among neonates hospitalized with sepsis (n=366) and NEC(n=150). Enrolled subjects will be randomized at the time of hospitalization to receive one dose of either 50,000 IU of vitamin A or placebo at enrollment, in addition to standard antibiotic therapy. We will compare the proportion of treatment failures in sepsis patients, the frequency of disease progression and mortality in NEC patients, and the time to clinical recovery and discharge between treatment groups. In addition, the study will determine whether vitamin A reduces pro-inflammatory cytokine levels; elevated host inflammatory cytokines are thought to contribute to the severity of both conditions. If vitamin A is found to be efficacious in the treatment of sepsis and NEC it could present a needed cost-effective approach to decreasing the global morbidity, mortality and the economic cost associated with neonatal sepsis and NEC in the developing world.

Interventions

DIETARY_SUPPLEMENTVitamin A

50,000 IU of Vitamin A 50,000 IU of vegetable oil

Sponsors

Bill and Melinda Gates Foundation
CollaboratorOTHER
United States Agency for International Development (USAID)
CollaboratorFED
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
CollaboratorNIH
Johns Hopkins University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
1 Days to 28 Days
Healthy volunteers
No

Inclusion criteria

* newborns less than 29 days with clinical sepsis

Exclusion criteria

* healthy infants * major congenital abnormalities * known inborn error(s) of metabolism * chronic disorders of other organs (e.g. cholestasis) * definite or severe NEC (\> stage 2) * congenital heart disease * Infants receiving VA supplements * Infants requiring mechanical ventilation * Infant is unconscious

Design outcomes

Primary

MeasureTime frame
Disease Mortalityprospective

Secondary

MeasureTime frame
Inflammatory cytokine concentrationprospective
Duration of inflammationprospective
Disease progression in NEC patientsprospective

Other

MeasureTime frame
Treatment failureprospective
Time to recovery from severe illnessprospective

Countries

Bangladesh

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026